StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note issued to investors on Saturday. The firm issued a sell rating on the stock.
Navidea Biopharmaceuticals Stock Performance
Shares of NYSE NAVB opened at $0.04 on Friday. The company has a market capitalization of $4.00 million, a P/E ratio of -0.57 and a beta of 1.13. Navidea Biopharmaceuticals has a 52-week low of $0.02 and a 52-week high of $0.30. The company’s 50 day moving average price is $0.04 and its 200-day moving average price is $0.05.
Institutional Trading of Navidea Biopharmaceuticals
An institutional investor recently raised its position in Navidea Biopharmaceuticals stock. Renaissance Technologies LLC grew its position in shares of Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) by 264.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 238,133 shares of the company’s stock after acquiring an additional 172,800 shares during the quarter. Renaissance Technologies LLC owned 0.74% of Navidea Biopharmaceuticals worth $62,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 0.01% of the stock is owned by institutional investors.
Navidea Biopharmaceuticals Company Profile
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.
See Also
- Five stocks we like better than Navidea Biopharmaceuticals
- How to Most Effectively Use the MarketBeat Earnings Screener
- Silicon Motion Proves That AI in Motion Stays in Motion
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Undervalued UnitedHealth Group Won’t Be For Long
- How to Use the MarketBeat Stock Screener
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
